Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analysts Admire Argenx's Vyvgart Launch

Pipeline-In-A-Product Off To Strong Start

Executive Summary

The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.

You may also be interested in...



AstraZeneca’s Ambitious Plans For Alexion

The UK major’s CEO, Pascal Soriot, said the setting-up of a new R&D hub in Cambridge, MA, which will also serve as the new corporate headquarters for Alexion, is "a milestone moment" for the rare diseases unit.

Argenx, Calliditas Hit The Ground Running After FDA Approvals

Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.

Almirall Views Vitiligo As Next Dermatology Opportunity

As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.

Topics

Related Companies

UsernamePublicRestriction

Register

SC146337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel